Skip to main content

Table 1 Baseline characteristics and design variables of the including studies

From: Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer

Article

Number (M/F)1

C/R/R-S2

Age Mean ± SD3/Median (range)

ST4

Cut-off

Rate(+)5

Follow up Mean ± SD/Median (range)

OM6

Surgery

MA7

Sotelo 2014 [24]

472(254/218)

425/47/0

Median:66(31–87)

Baseline

≥1/7.5 ml

166/472

Median:40(NR8)

OS9; PFS10

YES

NO

 

472(254/218)

425/47/0

Median:66(31–87)

Baseline

≥2/7.5 ml

93/472

Median:40(NR)

OS; PFS

YES

NO

 

472(254/218)

425/47/0

Median:66(31–87)

Baseline

≥3/7.5 ml

57/472

Median:40(NR)

OS; PFS

YES

NO

 

472(254/218)

425/47/0

Median:66(31–87)

Baseline

≥5/7.5 ml

34/472

Median:40(NR)

OS; PFS

YES

NO

Seeberg 2014 [25]

194(105/89)

124/70

Median:65(31–93)

Baseline

≥1/7.5 ml

37/189

Median:22.5(1–61)

OS; PFS

153YES

NO

 

194(105/89)

124/70

Median:65(31–93)

Baseline

≥2/7.5 ml

26/189

Median:22.5(1–61)

OS; PFS

153YES

YES

 

194(105/89)

124/70

Median:65(31–93)

Baseline

≥3/7.5 ml

17/189

Median:22.5(1–61)

OS; PFS

153YES

NO

Gazzaniga 2013 [26]

119(68/51)

NR

Median:64(29–84)

Baseline

≥1/7.5 ml

44/119

Median:12(1–26)

PFS

NR

YES

 

119(68/51)

NR

Median:64(29–84)

Baseline

≥3/7.5 ml

24/119

Median:12(1–26)

PFS

NR

YES

Aggarwal 2013 [27]

Baseline:209(NR)

NR

Mean:63.0 ± 12.6 Median: 64 (22–92)

Baseline

≥3/7.5 ml

62/209

median: NR(0.2-39.1)

OS

NR

YES

 

3-5 W:115(NR) 6-12 W:134(NR)

NR

NR

During-treatment: 3-5 W,6-12 W11

≥3/7.5 ml

3-5 W: 17/115; 6-12 W: 10/134

NR

OS

NR

YES

Kuboki 2013 [14]

63(34/29)

41/22/0

Median: 61(33–81)

Baseline

≥3/7.5 ml

19/63

Median:8.7(NR)

OS; PFS

NR

YES

Deneve 2013 [13]

69(43/26)

66/8/1

Median: 75(38–95)

Baseline

≥1/7.5 ml

20/69

Mean:31 ± NR Median:36 (0–52)

NR

YES

NO

Sastre 2012 [28]

Baseline:180(118/62)

40/121/19

Median: 65(40–82)

Baseline

≥3/7.5 ml

85/180

NR

OS; PFS

123YES

YES

 

Cycle3:147(NR)

NR

NR

Cycle3

≥3/7.5 ml

23/147

NR

OS; PFS

123YES

NO

Sato 2012 [29]

25(NR)

NR

NR

Baseline

≥3/7.5 ml

14/25

NR

OS

M1:NO12

NO

 

25(NR)

NR

NR

Baseline

≥1/7.5 ml

18/25

NR

OS

M1:NO

NO

Papavasiliou 2010 [30]

20(13/7)

NR

Median: 54 (41–81)

Baseline During-treatment

≥3/7.5 ml

Pre:2/20 intra: 10/20; post: 1/18

Median:11.5 (5–25)

OS; PFS

YES

NO

Tol 2010 [31]

467 (284/183)

225/122/ 120

Median: 63(27–83)

Baseline

≥3/7.5 ml

Baseline: 129/451

Median: 16.8(NR)

OS; PFS

NR

YES

 

1-2 W: 368(NR) 3-5 W:320(NR) 6-12 W:336(NR) 13-20 W: 254(NR)

NR

Median: 63(27–83)

During-treatment: 1-2/3-5/6-12/13-20 W

≥3/7.5 ml

1-2 W: 21/368; 3-5 W: 17/320; 6-12 W: 18/336; 13-20 W: 16/254

NR

OS; PFS

NR

YES

Hiraiwa 2008 [15]

40(NR)

NR

NR

Baseline + During-treatment

≥2/7.5 ml

14/40

NR

OS

YES

YES

  1. 1M/F: Male/female.
  2. 2C/R/R-S: Colon/Rectum/Rectosigmoid.
  3. 3SD: Standard deviation.
  4. 4ST: Sampling time.
  5. 5Rate(+): Rate of CTCs positive patients, n/N.
  6. 6OM: Outcome measured.
  7. 7MA: Multivariance analysis.
  8. 8NR: Not reported.
  9. 9OS: Overall survival.
  10. 10PFS: Progression-free survival.
  11. 11W: Week.
  12. 12M1: Tumor metastasis positive.